LIMN News & Events

Liminatus Pharma announced plans for a strategic expansion into the cryptocurrency and blockchain sector. The company intends to establish a dedicated subsidiary, named "American BNB Strategy," to lead its digital asset investment and management initiatives. Through this planned vehicle, Liminatus aims to raise and deploy up to $500 million in phases, targeting strategic, long-term investments in BNB coin the native token of the Binance ecosystem, the world's largest digital asset exchange. This announcement follows an internal review of blockchain-integrated financial strategies conducted over the past several weeks.

Liminatus Pharma announced that its Board of Directors and executive team have formally initiated a strategic review to explore the potential formation of a dedicated digital asset investment vehicle. The prospective subsidiary-which has not yet been formed and remains under active consideration-would operate independently of Liminatus's core clinical pipeline and focus on digital asset allocation and blockchain-integrated financial structures. If approved and executed, the Company anticipates targeting up to $500M in potential capital formation through a combination of private placements, convertible instruments, equity line and other structured financing tools. All fundraising activities, if undertaken, would be conducted in full alignment with applicable SEC regulations and exemptions. At this stage, no capital has been raised or committed, no agreements have been executed, and no third-party partnerships have been established. The internal review remains subject to final Board approval, regulatory compliance, and prevailing market conditions. Liminatus is working in close coordination with experienced legal, financial, and regulatory advisors to determine the optimal structure, governance, and compliance framework for the proposed initiative. The Company will provide further disclosures as appropriate, in accordance with SEC and Nasdaq reporting requirements.

Liminatus Pharma announced it has entered into an engagement agreement with Digital Offering to serve as its exclusive placement agent in connection with the company's evaluation of a potential strategic capital raise. This engagement supports Liminatus's previously disclosed review of a digital asset treasury strategy, as the company evaluates modern financial tools to strengthen its capital structure. The funding initiative may involve various exempt financing structures, including-but not limited to-convertible debentures, equity-linked securities, or other alternative instruments that comply with applicable U.S. securities laws. Under this engagement agreement, Digital Offering is engaged to assist the company in sourcing institutional and digital asset-focused investors and structuring a compliant financing solution.

Liminatus Pharma has initiated a strategic review to evaluate the potential inclusion of regulated digital asset strategies as part of its broader treasury management framework. This internal review is part of Liminatus's continued commitment to strong financial stewardship and balance sheet optimization. While its core focus remains firmly on advancing cancer therapies, the Company believes it is prudent to assess innovative financial instruments-including blockchain-based assets-that may enhance treasury efficiency and diversify non-operating capital reserves.